Abi-Saab Walid 4

What Happened

• Abi‑Saab Walid, Chief Medical Officer of uniQure N.V. (QURE), exercised stock options to acquire 10,000 shares at $5.59 per share (cost $55,900) on June 30, 2026. On the same date he sold a total of 30,000 shares in open‑market transactions for combined proceeds of $1,392,600 (weighted average prices reported). The Form 4 also reports a derivative disposition of 10,000 shares at $0.00 (reported as an M code).

Key Details

• Transaction date: June 30, 2026.
• Option exercise (M): 10,000 shares acquired at $5.59 each = $55,900.
• Derivative disposition (M): 10,000 shares reported at $0.00 (see filing).
• Open‑market sales (S): 10,000 shares at weighted avg $46.46 (sales prices ranged $46.19–$46.97) = $464,600; 20,000 shares at weighted avg $46.40 (prices ranged $46.24–$46.80) = $928,000. Total sales proceeds = $1,392,600.
• Net cash from the transactions (sales less exercise cost) ≈ $1,336,700.
• Shares owned after the transactions: not disclosed in the provided filing extract.
• Notable footnotes: sales were executed under a 10b5‑1 plan adopted Sept 26, 2025 (F1). Price entries are weighted averages with specified ranges (F2, F3). The option grant was on Mar 1, 2024 with a standard vesting schedule (F4).
• Filing timeliness: filing dated July 2, 2026 for June 30 transactions — no late filing indicated.

Context

• The filing shows same‑day option exercise and open‑market sales, consistent with exercising vested options and selling shares the same day (often done to cover exercise costs or diversify). The sales were executed under a prearranged 10b5‑1 plan, which typically indicates a preplanned trading schedule rather than ad hoc insider selling. As with all insider activity, sales are not necessarily a signal of company outlook; purchases tend to be more informative about insider conviction.